Autopsy report · NCT04418024

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.

“After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: Eidos Therapeutics, a BridgeBio company
Sponsor type: Industry
Conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Interventions: AG10; Placebo
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.